Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism

J. Trujillo-Santos, J. F. Bergmann, C. Bortoluzzi, R. López-Reyes, M. Giorgi-Pierfranceschi, J. B. López-Sáez, P. Ferrazzi, J. Bascuñana, J. M. Suriñach, M. Monreal

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Essentials In venous thromboembolism (VTE), it is uncertain if enoxaparin should be given twice or once daily. We compared the 15- and 30-day outcomes in VTE patients on enoxaparin twice vs. once daily. Patients on enoxaparin once daily had fewer major bleeds and deaths than those on twice daily. The rate of VTE recurrences was similar in both subgroups. Summary: Background In patients with acute venous thromboembolism (VTE), it is uncertain whether enoxaparin should be administered twice or once daily. Methods We used the RIETE Registry data to compare the 15- and 30-day rates of VTE recurrence, major bleeding and death between patients receiving enoxaparin twice daily and those receiving it once daily. We used propensity score matching to adjust for confounding variables. Results The study included 4730 patients: 3786 (80%) received enoxaparin twice daily and 944 once daily. During the first 15 days, patients on enoxaparin once daily had a trend towards more VTE recurrences (odds ratio [OR], 1.79; 95% confidence interval [CI], 0.55–5.88), fewer major bleeds (OR, 0.42; 95% CI, 0.17–1.08) and fewer deaths (OR, 0.32; 95% CI, 0.13–0.78) than those on enoxaparin twice daily. At day 30, patients on enoxaparin once daily had more VTE recurrences (OR, 2.5; 95% CI, 1.03–5.88), fewer major bleeds (OR, 0.40; 95% CI, 0.17–0.94) and fewer deaths (OR, 0.58; 95% CI, 0.33–1.00). On propensity analysis, patients on enoxaparin once daily had fewer major bleeds at 15 (hazard ratio [HR], 0.30; 95% CI, 0.10–0.88) and at 30 days (HR, 0.16; 95% CI, 0.04–0.68) and also fewer deaths at 15 (HR, 0.37; 95% CI, 0.14–0.99) and at 30 days (HR, 0.19; 95% CI, 0.07–0.54) than those on enoxaparin twice daily. Conclusions Our findings confirm that enoxaparin prescribed once daily results in fewer major bleeds than enoxaparin twice daily, as suggested in a meta-analysis of controlled clinical trials.

Original languageEnglish
Pages (from-to)429-438
Number of pages10
JournalJournal of Thrombosis and Haemostasis
Volume15
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Enoxaparin
Venous Thromboembolism
Confidence Intervals
Odds Ratio
Therapeutics
Recurrence
Propensity Score
Confounding Factors (Epidemiology)
Controlled Clinical Trials
Registries
Meta-Analysis

Keywords

  • bleeding
  • enoxaparin
  • mortality
  • recurrences
  • regimen
  • venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

Trujillo-Santos, J., Bergmann, J. F., Bortoluzzi, C., López-Reyes, R., Giorgi-Pierfranceschi, M., López-Sáez, J. B., ... Monreal, M. (2017). Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism. Journal of Thrombosis and Haemostasis, 15(3), 429-438. https://doi.org/10.1111/jth.13616

Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism. / Trujillo-Santos, J.; Bergmann, J. F.; Bortoluzzi, C.; López-Reyes, R.; Giorgi-Pierfranceschi, M.; López-Sáez, J. B.; Ferrazzi, P.; Bascuñana, J.; Suriñach, J. M.; Monreal, M.

In: Journal of Thrombosis and Haemostasis, Vol. 15, No. 3, 01.03.2017, p. 429-438.

Research output: Contribution to journalArticle

Trujillo-Santos, J, Bergmann, JF, Bortoluzzi, C, López-Reyes, R, Giorgi-Pierfranceschi, M, López-Sáez, JB, Ferrazzi, P, Bascuñana, J, Suriñach, JM & Monreal, M 2017, 'Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism', Journal of Thrombosis and Haemostasis, vol. 15, no. 3, pp. 429-438. https://doi.org/10.1111/jth.13616
Trujillo-Santos J, Bergmann JF, Bortoluzzi C, López-Reyes R, Giorgi-Pierfranceschi M, López-Sáez JB et al. Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism. Journal of Thrombosis and Haemostasis. 2017 Mar 1;15(3):429-438. https://doi.org/10.1111/jth.13616
Trujillo-Santos, J. ; Bergmann, J. F. ; Bortoluzzi, C. ; López-Reyes, R. ; Giorgi-Pierfranceschi, M. ; López-Sáez, J. B. ; Ferrazzi, P. ; Bascuñana, J. ; Suriñach, J. M. ; Monreal, M. / Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism. In: Journal of Thrombosis and Haemostasis. 2017 ; Vol. 15, No. 3. pp. 429-438.
@article{f0bda713e4b64ff9a7bedf474f7343ba,
title = "Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism",
abstract = "Essentials In venous thromboembolism (VTE), it is uncertain if enoxaparin should be given twice or once daily. We compared the 15- and 30-day outcomes in VTE patients on enoxaparin twice vs. once daily. Patients on enoxaparin once daily had fewer major bleeds and deaths than those on twice daily. The rate of VTE recurrences was similar in both subgroups. Summary: Background In patients with acute venous thromboembolism (VTE), it is uncertain whether enoxaparin should be administered twice or once daily. Methods We used the RIETE Registry data to compare the 15- and 30-day rates of VTE recurrence, major bleeding and death between patients receiving enoxaparin twice daily and those receiving it once daily. We used propensity score matching to adjust for confounding variables. Results The study included 4730 patients: 3786 (80{\%}) received enoxaparin twice daily and 944 once daily. During the first 15 days, patients on enoxaparin once daily had a trend towards more VTE recurrences (odds ratio [OR], 1.79; 95{\%} confidence interval [CI], 0.55–5.88), fewer major bleeds (OR, 0.42; 95{\%} CI, 0.17–1.08) and fewer deaths (OR, 0.32; 95{\%} CI, 0.13–0.78) than those on enoxaparin twice daily. At day 30, patients on enoxaparin once daily had more VTE recurrences (OR, 2.5; 95{\%} CI, 1.03–5.88), fewer major bleeds (OR, 0.40; 95{\%} CI, 0.17–0.94) and fewer deaths (OR, 0.58; 95{\%} CI, 0.33–1.00). On propensity analysis, patients on enoxaparin once daily had fewer major bleeds at 15 (hazard ratio [HR], 0.30; 95{\%} CI, 0.10–0.88) and at 30 days (HR, 0.16; 95{\%} CI, 0.04–0.68) and also fewer deaths at 15 (HR, 0.37; 95{\%} CI, 0.14–0.99) and at 30 days (HR, 0.19; 95{\%} CI, 0.07–0.54) than those on enoxaparin twice daily. Conclusions Our findings confirm that enoxaparin prescribed once daily results in fewer major bleeds than enoxaparin twice daily, as suggested in a meta-analysis of controlled clinical trials.",
keywords = "bleeding, enoxaparin, mortality, recurrences, regimen, venous thromboembolism",
author = "J. Trujillo-Santos and Bergmann, {J. F.} and C. Bortoluzzi and R. L{\'o}pez-Reyes and M. Giorgi-Pierfranceschi and L{\'o}pez-S{\'a}ez, {J. B.} and P. Ferrazzi and J. Bascu{\~n}ana and Suri{\~n}ach, {J. M.} and M. Monreal",
year = "2017",
month = "3",
day = "1",
doi = "10.1111/jth.13616",
language = "English",
volume = "15",
pages = "429--438",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism

AU - Trujillo-Santos, J.

AU - Bergmann, J. F.

AU - Bortoluzzi, C.

AU - López-Reyes, R.

AU - Giorgi-Pierfranceschi, M.

AU - López-Sáez, J. B.

AU - Ferrazzi, P.

AU - Bascuñana, J.

AU - Suriñach, J. M.

AU - Monreal, M.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Essentials In venous thromboembolism (VTE), it is uncertain if enoxaparin should be given twice or once daily. We compared the 15- and 30-day outcomes in VTE patients on enoxaparin twice vs. once daily. Patients on enoxaparin once daily had fewer major bleeds and deaths than those on twice daily. The rate of VTE recurrences was similar in both subgroups. Summary: Background In patients with acute venous thromboembolism (VTE), it is uncertain whether enoxaparin should be administered twice or once daily. Methods We used the RIETE Registry data to compare the 15- and 30-day rates of VTE recurrence, major bleeding and death between patients receiving enoxaparin twice daily and those receiving it once daily. We used propensity score matching to adjust for confounding variables. Results The study included 4730 patients: 3786 (80%) received enoxaparin twice daily and 944 once daily. During the first 15 days, patients on enoxaparin once daily had a trend towards more VTE recurrences (odds ratio [OR], 1.79; 95% confidence interval [CI], 0.55–5.88), fewer major bleeds (OR, 0.42; 95% CI, 0.17–1.08) and fewer deaths (OR, 0.32; 95% CI, 0.13–0.78) than those on enoxaparin twice daily. At day 30, patients on enoxaparin once daily had more VTE recurrences (OR, 2.5; 95% CI, 1.03–5.88), fewer major bleeds (OR, 0.40; 95% CI, 0.17–0.94) and fewer deaths (OR, 0.58; 95% CI, 0.33–1.00). On propensity analysis, patients on enoxaparin once daily had fewer major bleeds at 15 (hazard ratio [HR], 0.30; 95% CI, 0.10–0.88) and at 30 days (HR, 0.16; 95% CI, 0.04–0.68) and also fewer deaths at 15 (HR, 0.37; 95% CI, 0.14–0.99) and at 30 days (HR, 0.19; 95% CI, 0.07–0.54) than those on enoxaparin twice daily. Conclusions Our findings confirm that enoxaparin prescribed once daily results in fewer major bleeds than enoxaparin twice daily, as suggested in a meta-analysis of controlled clinical trials.

AB - Essentials In venous thromboembolism (VTE), it is uncertain if enoxaparin should be given twice or once daily. We compared the 15- and 30-day outcomes in VTE patients on enoxaparin twice vs. once daily. Patients on enoxaparin once daily had fewer major bleeds and deaths than those on twice daily. The rate of VTE recurrences was similar in both subgroups. Summary: Background In patients with acute venous thromboembolism (VTE), it is uncertain whether enoxaparin should be administered twice or once daily. Methods We used the RIETE Registry data to compare the 15- and 30-day rates of VTE recurrence, major bleeding and death between patients receiving enoxaparin twice daily and those receiving it once daily. We used propensity score matching to adjust for confounding variables. Results The study included 4730 patients: 3786 (80%) received enoxaparin twice daily and 944 once daily. During the first 15 days, patients on enoxaparin once daily had a trend towards more VTE recurrences (odds ratio [OR], 1.79; 95% confidence interval [CI], 0.55–5.88), fewer major bleeds (OR, 0.42; 95% CI, 0.17–1.08) and fewer deaths (OR, 0.32; 95% CI, 0.13–0.78) than those on enoxaparin twice daily. At day 30, patients on enoxaparin once daily had more VTE recurrences (OR, 2.5; 95% CI, 1.03–5.88), fewer major bleeds (OR, 0.40; 95% CI, 0.17–0.94) and fewer deaths (OR, 0.58; 95% CI, 0.33–1.00). On propensity analysis, patients on enoxaparin once daily had fewer major bleeds at 15 (hazard ratio [HR], 0.30; 95% CI, 0.10–0.88) and at 30 days (HR, 0.16; 95% CI, 0.04–0.68) and also fewer deaths at 15 (HR, 0.37; 95% CI, 0.14–0.99) and at 30 days (HR, 0.19; 95% CI, 0.07–0.54) than those on enoxaparin twice daily. Conclusions Our findings confirm that enoxaparin prescribed once daily results in fewer major bleeds than enoxaparin twice daily, as suggested in a meta-analysis of controlled clinical trials.

KW - bleeding

KW - enoxaparin

KW - mortality

KW - recurrences

KW - regimen

KW - venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85013447201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013447201&partnerID=8YFLogxK

U2 - 10.1111/jth.13616

DO - 10.1111/jth.13616

M3 - Article

C2 - 28120516

AN - SCOPUS:85013447201

VL - 15

SP - 429

EP - 438

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 3

ER -